NeoGenomics Inc. Common Stock (NEO) fair value

ACCE thesis

NeoGenomics runs a cancer-focused diagnostics business, selling oncology testing services (including its RaDaR residual disease and NeoLife tumour profiling tests) to oncologists and pharma partners rather than selling instruments. The structural case rests on that oncology focus: testing volumes track cancer diagnosis and treatment decisions, which are growing and increasingly tied to molecular profiling. Revenue is growing 11.2%, but the company is still not profitable, with a -4.8% operating margin and -6.3% return on equity, and a 43.9% gross margin leaves room for operating leverage if volumes keep rising. The forward P/E of 222 means the market is pricing in a large earnings ramp that has not yet shown up, so the investment question is whether margin expansion arrives on the timeline the valuation requires. It is worth a deeper look only if you can get comfortable with that gap between current losses and the earnings the stock implies, and with the fact that it sits in no major index, which limits passive demand.